Colorectal cancer is no longer considered a chemotherapy-resistant malignancy. A 1985 study outlined the benefits of first-line, single agent 5-fluorouracil, describing tumor response rates of only 23% and a median survival of only 8.7 months ([@b3-tcrm-4-1363]). No extra benefits were reported with the addition of other chemotherapy drugs ([@b3-tcrm-4-1363]).

Contrast these dismal results to more recent findings. [@b4-tcrm-4-1363] demonstrated that a multidrug, first-line regimen, which consisted of oxaliplatin, leucovorin, and 5-fluorouracil, yielded a tumor response rate of 45%, nearly double that reported earlier, and stretched the median survival by over two-fold, to 19.5 months. Such findings underscore the major therapeutic strides that have occurred in the management of patients with metastatic colorectal cancer and demonstrate that this previously chemotherapy-resistant malignancy can now be viewed as chemosensitive.

Have such breakthroughs changed our approach? Are we now at the point where patients, who were formerly considered marginal candidates for chemotherapy, can be prescribed it routinely? Specifically, should patients with liver metastases and marked hyperbilirubinemia now be prescribed chemotherapy in the hope of improving their hepatic function and improving their clinical outcomes? To our knowledge, these questions have not yet been answered because large, prospective clinical trials typically require that patients enroll with normal or near-normal organ function. Moreover, to date, only small case reports, some of which are not totally relevant to the questions posed above, have served to provide guidance on clinical management ([@b13-tcrm-4-1363]; [@b5-tcrm-4-1363]; [@b7-tcrm-4-1363]). Hence, the purpose of the present study was to report outcomes within a group of colorectal cancer patients with severe hyperbilirubinemia presumably from liver metastases in an effort to provide more substantive guidance in answering the question of whether these patients benefit from state-of-the-art chemotherapy.

Methods
=======

Overview
--------

The Mayo Clinic Institutional Review Board approved the study protocol prior to its implementation. The Mayo Clinic Tumor Registry then provided information on all patients seen at the Mayo Clinic in Rochester, Minnesota USA with a diagnosis of colorectal cancer between the years of 2002 through 2006. The rationale for choosing 2002 as the start year rests in the fact that, by this time, oxaliplatin, an effective, non-liver metabolized drug, had been approved by the Food and Drug Administration for clinical use in colorectal cancer patients ([@b2-tcrm-4-1363]).

Screening process of medical records
------------------------------------

All medical records provided by the Tumor Registry were then screened by one investigator (TW) to identify patients who met the study team's *a priori* selection criteria. These criteria included severe hyperbilirubinemia (defined below), unresectable metastatic colorectal cancer, and no prior colorectal cancer therapy (no prior surgery, radiation, or chemotherapy). With regard to the latter point, a deliberate decision was made to select colorectal cancer patients with a newly diagnosed malignancy, as those with recurrent disease were likely to tolerate chemotherapy poorly as a result of prior surgery, radiation, or chemotherapy, thereby potentially biasing conclusions negatively ([@b6-tcrm-4-1363]; [@b8-tcrm-4-1363]; [@b10-tcrm-4-1363]).

Severe organ dysfunction was initially defined on the basis of hyperbilirubinemia because of the proclivity of colorectal cancer to metastasize to the liver. Patients who had a serum total bilirubin of 3 mg/dL or greater in the absence of previous cancer therapy were the focus of this study. This threshold was chosen because another effective drug in colorectal cancer, irinotecan, is contraindicated at this serum bilirubin level for safety reasons ([@b9-tcrm-4-1363]), a fact that emphasizes the grave nature of this degree of hyperbilirubinemia. Thus, it appeared reasonable to target patients with this degree of organ dysfunction and to utilize this serum bilirubin threshold in the screening process.

In depth review of medical records
----------------------------------

The medical records of patients identified in this screening process were then reviewed in depth. One investigator (TW) reviewed these medical records, and another investigator (AJ) confirmed specific information.

Information on patient age at cancer diagnosis, gender, relevant laboratory data, method of assessing the presence of liver metastases, whether liver metastases were in fact present, the number and type of chemotherapy regimens prescribed, whether a biliary stent was placed, adverse events, and overall survival were gleaned from each medical record. Tumor response was not assessed because of inconsistent patterns in radiographic testing from patient to patient and because of the greater value placed on survival ([@b1-tcrm-4-1363]; [@b12-tcrm-4-1363]). It was also decided not to attempt to glean information on performance status in view of inconsistent reporting and attribution from physician to physician ([@b11-tcrm-4-1363]).

Data analyses
-------------

This study was intended to be descriptive; all demographic and outcome data are presented as such. Survival is defined as the interval between cancer diagnosis and date of death. In the event that the date of death was unknown, data were censored from the date of last follow up. JMP version 6 (SAS Inc., Cary, NC) was used to construct Kaplan--Meier survival curves.

Results
=======

Patient demographics
--------------------

A total of 3,019 patients were initially identified by the Mayo Clinic Tumor Registry. The vast majority was found to have a serum bilirubin \<3 mg/dL and/or to have received prior cancer treatment. Nonetheless, the screening process yielded 20 patients who met the selection criteria.

Among these 20 patients, 11 were male (55%), and the median age at colorectal cancer diagnosis was 54 years (range 39, 81) ([Table 1](#t1-tcrm-4-1363){ref-type="table"}). Only 2 had rectal cancer, and the remaining colon cancer. The median bilirubin level was 6.4 mg/dL (range 3.1, 28 mg/dL). All had liver metastases, as seen by computed tomography (17 patients), ultrasound (1 patient), or surgical exploration or biopsy (2 patients). Hyperbilirubinemia was not attributable to hemolysis in any patient, and, in effect, review of the medical record did not show any apparent nonbiliary or nonhepatic cause.

Six patients received chemotherapy, and 12 received only supportive care. In two patients, the medical record did not document chemotherapy administration or the decision to resort to supportive care exclusively, but one of these patients was alive at 394 days after diagnosis. In this patient, internal and external records show a recommendation to proceed with an oxaliplatin-based regimen in combination with bevacizumab. Well documented, first-line chemotherapy in the other patients included: oxaliplatin, 5-fluorouracil, and leucovorin (three patients); oxaliplatin, 5-fluorouracil, leucovorin, and bevacizumab (one patient); and oxaliplatin and capecitabine (one patient). Second-line chemotherapy that consisted of irinotecan, 5-fluorouracil, and leucovorin was administered to one patient.

The median survival of the six chemotherapy-treated patients was 71 days. Among the 12 nontreated patients, it was 28 days ([Figure 1](#f1-tcrm-4-1363){ref-type="fig"}).

Chemotherapy and/or biliary stent placement was associated with a drop in bilirubin in four patients ([Table 2](#t2-tcrm-4-1363){ref-type="table"}). Chemotherapy alone was associated with a decrease in bilirubin in two patients, leading to a decline from 27.7 to 2.5 mg/dL in one and a modest decline from 6.5 to 5.7 mg/dL in another. It is impossible to say that this decline is definitely attributable to the chemotherapy. In five patients, a stent was placed, and two of these patients also received chemotherapy. It appears that the nonstented patients had hepatic dysfunction related to intra-parenchymal liver disease. In one of these stented, chemotherapy-treated patients, the bilirubin dropped from 16.2 mg/dL to a normal level of 0.6 mg/dL; and, in the other, it dropped from 12.5 mg/dL to 3 mg/dL. In the three other patients who underwent only stent placement, the bilirubin stayed the same in one, increased in another, and apparently was not rechecked in the third.

In terms of adverse events, severe fatigue was noted in one patient who received chemotherapy. Another suffered from mucositis and dehydration after chemotherapy. This same patient was hospitalized and died from a gastrointestinal bleed approximately five weeks after receiving bevacizumab (Patient \#2 in [Table 2](#t2-tcrm-4-1363){ref-type="table"}).

Discussion
==========

To our knowledge, this study is one of the few to evaluate outcomes in colorectal cancer patients with liver metastases and severe hyperbilirubinemia. Overall, these 20 patients did poorly. None achieved the median survival of 19.5 months, as reported by [@b4-tcrm-4-1363]; and, in fact, only one was confirmed to live beyond the one-year mark. The observations that patients who received chemotherapy lived relatively longer and at times manifested a decline in bilirubin suggest that chemotherapy was providing antineoplastic effects. Hence, a small subgroup of patients with colorectal cancer, liver metastases, and severe hyperbilirubinemia appears to derive modest benefits from chemotherapy.

It is important to point out the limitations of this study. First, patients who received chemotherapy may have been more fit, better able to tolerate it, and therefore more likely to derive benefit from it. In the absence of a randomized, controlled trial, the best we can conclude is that a subgroup of patients with hyperbilirubinemia appears to benefit. It remains unclear whether chemotherapy provides better outcomes compared to supportive care alone. Second, although this study observed that one patient did die from a chemotherapy-related complication, the retrospective design of this study might predispose to the underreporting of adverse events. Thus, we cannot claim that the risk to benefit ratio of chemotherapy clearly justifies its administration, despite the fact that the median survival was greater among chemotherapy-treated patients. Third, although it is tantalizing to conclude that perhaps patients with hyperbilirubinemia in the setting of other malignancies would also potentially benefit from chemotherapy, this conclusion would be perilous. Further study of hyperbilirubinemia in other cancer settings is indicated before such conclusions can be drawn.

The question of whether or not to attempt to place a stent in patients with biliary obstruction also remains unanswered. This study included only two patients who had had a biliary stent placed and who did not receive subsequent chemotherapy. These two patients manifested little clinical improvement. Although no firm conclusions can be drawn, we might begin to question the value of stenting a patient in the absence of plans to initiate subsequent chemotherapy. This issue perhaps merits further study.

In summary, the present study provides justification for prescribing chemotherapy to patients with colorectal cancer, liver metastases, and hyperbilirubinemia. However, given the poor outcome in this series as a whole, it remains prudent to continue to rely on clinical judgment in making therapeutic decisions and to discuss risks and benefits with patients and their families at length prior to prescribing chemotherapy.
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###### 

Baseline characteristics (n = 20)

  ---------------------------- ---------------
  Age (in years)               
    Median (range)             54 (39, 81)
  Gender                       
    Male (%)                   11 (55)
    Female (%)                 9 (45)
  Serum bilirubin (in mg/dL)   
    Median (range)             6.4 (3.1, 28)
  Cancer site                  
    Colon (%)                  18 (90)
    Rectum (%)                 2 (10)
  ---------------------------- ---------------

###### 

Outcomes among the nine chemotherapy-treated and/or stented patients

                                         1                                                                                      2                                                      3      4                           5      6                                          7                                          8                                                      9
  -------------------------------------- -------------------------------------------------------------------------------------- ------------------------------------------------------ ------ --------------------------- ------ ------------------------------------------ ------------------------------------------ ------------------------------------------------------ ---------
  Age (years)                            56                                                                                     81                                                     80     49                          51     46                                         62                                         53                                                     57
  Gender                                 Male                                                                                   Female                                                 Male   Male                        Male   Male                                       Male                                       Male                                                   Male
  Total bilirubin at diagnosis (mg/dL)   16.2                                                                                   27.7                                                   13.8   6.2                         4.4    3.5                                        12.5                                       6.5                                                    3.2
  Stent placement at diagnosis           Yes                                                                                    No                                                     Yes    No                          Yes    No                                         Yes                                        No                                                     Yes
  Chemotherapy                           Oxaliplatin, 5-fluorouracil, Leucovorin, then irinotecan, 5-fluorouracil, leucovorin   Oxaliplatin, 5-fluorouracil, Leucovorin, bevacizumab   None   Oxaliplatin, capecitabine   None   Oxaliplatin, 5-fluorouracil, Leucovorin,   Oxaliplatin, 5-fluorouracil, Leucovorin,   Oxaliplatin, 5-fluorouracil, Leucovorin, bevacizumab   Unknown
  Drop in bilirubin?                     Yes                                                                                    Yes                                                    No     No                          No     No                                         Yes                                        Yes                                                    Unknown
  Survival (days)^\*^                    283                                                                                    59                                                     86     24                          23+    46                                         170+                                       71                                                     394+

**Note:** \*Censored data are denoted by a + sign.
